ClinicalTrials.gg
Not yet recruitingNCT07115251Updated Aug 11, 2025

Plans4Care: Personalized Dementia Care on Demand

A Phase 2 interventional study of Plans4Care in Dementia, Dementia Alzheimer Type and Alzheimer Dementia (AD), sponsored by Plans4Care Inc. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Plans4Care Inc · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms (anxiety, agitation), functional changes and other concerns, and receive an action plan which provides easy-to-use non-drug strategies, resources, tips and education.

The goal of the study is to evaluate whether using the Plans4Care app will help you feel more confident providing care to your family member with dementia, better understand dementia, and enhance your own well-being. You also have the option to talk with a care advisor who can practice use of strategies or address concerns you may have.

Read the detailed description

We invite caregivers of people with dementia to take part in this research study. You are being asked to evaluate a new online application (web app) called Plans4Care that provides personalized action plans to address common dementia-related care challenges including tips for your own health and wellbeing. This study is being conducted by Plans4Care, Inc. and researchers at Drexel University in collaboration with Thomas Jefferson University.

Participants who are eligible for this study are:

  1. A family, friend, or neighbor who self-identifies as having primary care responsibilities for a person with memory loss;
  2. >21 years of age;
  3. Able to use an internet capable device (computer, tablet or smart phone), and have stable internet access;

6. Actively (e.g., past 6 months) managing a dementia-related care challenge.

02

Conditions studied

  • Dementia
  • Dementia Alzheimer Type
  • Alzheimer Dementia (AD)
  • Memory Loss

Browse trials for

Keywords

  • Caregiver, Dementia, Memory Loss, Alzheimer
03

In context

Alzheimer Disease Reclassified

3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.

This study's planned enrollment of 160 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

This is the only study on the registry with Plans4Care Inc as lead sponsor.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. A family, friend, or neighbor who self-identifies as having primary care responsibilities for a person with memory loss;
  2. >21 years of age;
  3. Able to use an internet capable device (computer, tablet or smart phone), and have stable internet access;

6. Actively (e.g., past 6 months) managing a dementia-related care challenge.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    initial treatment group

    Receives Plans4Care web app

    Behavioral: Plans4Care

  • Other
    Waitlist control

    At 6 months, receives access to the Plans4Care web app

    Behavioral: Plans4Care

Interventions

  • BehavioralPlans4Care

    Caregivers assigned to treatment condition will receive: 1) access to the web-app; 2) an orientation to the web-app involving initial set up; and 3) a brief video explaining use of the web-app. Caregivers will be guided through accessing the platform, creating an account and completing a brief set of background questions.

    Also known as: P4C

06

What researchers measure

Primary outcomes

  1. Caregiver well-being

    13-item validated Perceived Change for Better Index assesses caregiver perceived change (gotten worse-a little/a lot, stayed the same, improved-a little/a lot) in affect, somatic, manage daily care.

    Time frame: Baseline, 3 months, 6 months and 12 months

Secondary outcomes

  1. Caregiver/customer satisfaction (outcome) Net promoter Score

    "How likely is it that you would recommend Plans4Care to a friend or colleague?" (0=not at all to 10=extremely likely). Promoters = score 9 or 10; Passives = score 7 or 8. Detractors = score=0 to 6

    Time frame: 6 months and 12 months

  2. Caregiver satisfaction survey

    A questionnaire designed to gauge how satisfied caregivers are with their work, including their work environment, support systems, and overall job satisfaction.

    Time frame: 6 months and 12 months

  3. Health care utilization

    Caregiver report 911 calls, emergency room visits, hospitalizations, nursing home placement for person with AD/ADRD Electronic records from primary care practices of emergency room visits and days hospitalized

    Time frame: Baseline, 3 months, 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2027, 24 months later.

Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 24 months is close to that.

Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartEst.
Aug 30, 2025
Primary completionEst.
Aug 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07115251
Lead sponsor
Plans4Care Inc
Responsible party
Sokha Koeuth (MPI, Plans4Care Inc) — Principal investigator
First posted
Aug 11, 2025
Start date
Aug 30, 2025 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 11, 2025

Study contacts

Sokha Koeuth, DHSc
Contact
sokha_koeuth@plans4care.com
12153008483
Eric Jutkowitz, PhD
Contact
eric_jutkowitz@plans4care.com
215-421-9728
Sokha Koeuth, DHSc
principal investigator · Plans4Care Inc
Eric Jutkowitz, PhD
principal investigator · Plans4Care Inc
Laura N. Gitlin, PhD, FGSA,FAAN
study director · Drexel University
Catherine V Piersol, PhD, OTR/L,FAOTA, FNAP
study director · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion